Boehringer Ingelheim』s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

首圖

INGELHEIM, Germany--(BUSINESS WIRE)--Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was published in&nb......